Bin Rubaian Nouf F, Almuhaidib Seereen R, Aljarri Shadan A, Alamri Areen S
Department of Dermatology, Imam Abdulrahman bin Faisal University, Al Khobar, SAU.
Cureus. 2022 Jul 21;14(7):e27108. doi: 10.7759/cureus.27108. eCollection 2022 Jul.
Pityriasis rosea (PR) is an acute self-limiting exanthematous skin disorder characterized by the presence of a primary solitary lesion called a herald patch and the subsequent development of diffuse papulosquamous lesions within 1 to 2 weeks. This is a case of COVID-19 vaccine-induced PR in the age group (12-18 years) that was recently approved for vaccination. We report a case of a 15-year-old otherwise healthy female with a history of 2 weeks of single oval primary plaque appearing on the right wrist 2 days after receiving the second dose of Pfizer-BioNTech vaccine, followed by diffuse and mild itchy skin eruptions spreading over the abdomen, back, chest, and extremities. The patient had no other symptoms and no PR risk factors. The patient was placed on 800 mg acyclovir five times a day and improved markedly after 1 week. As vaccine-induced PR/PR-like eruptions (PR-LE) is an uncommon phenomenon, we recommend further studies to determine the association between PR/PR-LE and COVID-19 vaccination.
玫瑰糠疹(PR)是一种急性自限性发疹性皮肤病,其特征为存在一个称为先驱斑的原发性孤立损害,随后在1至2周内出现弥漫性丘疹鳞屑性损害。这是一例在最近获批接种疫苗的年龄组(12 - 18岁)中由新冠疫苗诱发的玫瑰糠疹病例。我们报告了一例15岁健康女性病例,该患者在接种第二剂辉瑞 - 生物科技疫苗2天后,右腕部出现单个椭圆形原发性斑块,持续2周,随后腹部、背部、胸部和四肢出现弥漫性轻度瘙痒性皮疹。患者无其他症状,也无玫瑰糠疹风险因素。患者接受每天5次、每次800毫克阿昔洛韦治疗,1周后明显好转。由于疫苗诱发的玫瑰糠疹/玫瑰糠疹样皮疹(PR - LE)是一种罕见现象,我们建议进一步研究以确定PR/PR - LE与新冠疫苗接种之间的关联。